How your gut microbes drive vitiligo's white patches

You think of vitiligo as a skin condition. But a new study suggests those pale patches begin much deeper: in the gut, where certain bacteria produce a molecule that travels through the blood and slowly bleaches the skin from within.

The gut microbiota
Photo: How your gut microbes drive vitiligo's white patches

Vitiligo affects up to one in fifty people worldwide. It appears as pale, depigmented patches where the skin's pigment-making cells, (sidenote: Melanocyte The specialised cell that produces melanin, the pigment giving skin its colour and protecting it from sunlight. When melanocytes are damaged or destroyed, as in vitiligo, the skin loses its tone in the affected areas. ) , have fallen silent or died. For decades, dermatologists have focused on calming the skin itself, with steroid creams, ultraviolet lamps and, increasingly, lasers. Yet patches often return. A team of Chinese researchers 1 suspected the real trouble might be starting somewhere else entirely: the gut.

Vitiligo

A chronic skin condition in which the body's own immune system turns against melanocytes, the cells that colour the skin, eyes and hair. As melanocytes disappear, pale patches slowly take their place. 

A long-distance signal between gut and skin

Using a mouse model of vitiligo, the team showed that when they wiped out the animals' gut bacteria with antibiotics, the depigmenting patches shrank and the skin's level of (sidenote: Oxidative stress A chemical imbalance inside cells in which reactive, unstable molecules, often compared to sparks, begin to damage proteins, DNA and membranes. In vitiligo, this slow-burning damage is thought to push melanocytes toward death. ) , a kind of cellular rusting that damages (sidenote: Melanocyte The specialised cell that produces melanin, the pigment giving skin its colour and protecting it from sunlight. When melanocytes are damaged or destroyed, as in vitiligo, the skin loses its tone in the affected areas. ) , dropped sharply. 

But when they placed different groups of vitiligo-affected mice together in the same cage, allowing their microbes to mix, the younger animals co-housed with older mice developed worse patches than those kept apart. The gut, it seems, was quietly pulling strings far above its own address.

Meet hippuric acid, the unlikely messenger

Screening hundreds of molecules in feces, blood and skin, the scientists kept arriving at the same suspect: (sidenote: Hippuric acid A small molecule made when gut bacteria digest plant compounds found in fruits, vegetables, tea and coffee. Normally harmless, it turns out to rise sharply in vitiligo and, this study argues, travels from gut to skin to fuel the damage there. ) , a small acid that gut microbes help produce from plant compounds in food. In vitiligo mice, hippuric acid was piled up in the skin at roughly five times normal levels. Injected into healthy mice, it reproduced the same chemical damage. Even more telling, when the researchers measured blood from 15 people with active vitiligo, their hippuric acid was nearly twice that of healthy volunteers.

0.5% to 2% Vitiligo affects roughly 0.5 to 2% of the world's population.

A leaky barrier and a surprising treatment hint

How did a gut molecule reach the skin in such quantities? The vitiligo mice had fewer goblet cells, the tiny factories that line the intestine with protective mucus. With that inner lining thinned, hippuric acid slipped more easily into the bloodstream and travelled outward, ultimately latching onto two proteins in skin cells, NOS2 and MAPK14, that crank up oxidative damage.

The hopeful twist: feeding the mice a probiotic mixture visibly slowed their depigmentation. For a condition that carries a quiet emotional weight for millions, that is a new direction worth watching. Human trials will need to confirm it, but the finding opens a therapeutic door vitiligo has rarely looked through.

Your skin does not stand alone. What unfolds on it can be authored pages away, in a place you cannot see. Treating vitiligo may one day mean mending that distant text, not only the mark it left behind.

Feel good in your skin... and your skin microbiota

Learn more
Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Do early-life bifidobacteria reduce allergies?

Certain bifidobacteria found in an infant’s gut, promoted particularly by breastfeeding, could provide long-term protection against allergies by limiting production of the antibodies involved.

The gut microbiota

Allergic diseases (eczema, asthma, food allergies) often appear very early in life and are becoming more common. They therefore raise a crucial question: how do these allergic traits develop? And how can we counter them?

16 % Food allergen sensitization affects up to 16% of all infants in low- and high-income countries. ¹

A question of bifidobacteria

A study 1 published at the beginning of 2026 in the journal Nature Microbiology suggests that part of the story unfolds very early, through bacterial colonization of infants’ guts. In particular, certain bifidobacteria carry a specific gene (ALDH) that allows them to transform aromatic amino acids from breast milk into their respective aromatic lactates.

These lactates have a beneficial effect on the child’s developing immune system. One of them in particular is 4-OH-PLA, an aromatic lactate that appears to reduce the production of antibodies called IgE (immunoglobulin E), involved in the development of allergies. It is also associated with a lower incidence of atopic dermatitis at two years of age.

x14 Vaginal delivery was associated with a 14-fold higher odds of maternal strain colonization than caesarean section. ¹

A very short time window

These processes occur early and pass quickly: the protective effect of ALDH+ bifidobacteria in the gut microbiota is thought to exist for only a very limited period, up to 5 to 6 months of age. During this period, which generally corresponds to breastfeeding, bifidobacteria are most abundant in the digestive system and 4-OH-PLA production is at its peak. The diversification of the diet (introduction of solid foods) then changes everything.
There may thus be a “critical window” in the infant’s immune development during which a gut microbiota rich in ALDH+ bifidobacteria can have a lasting influence on allergy risk later in childhood and adulthood.

Microbiota imbalance at age one predicts allergies at age five

Learn more

Factors that support this protective mechanism

According to the study, several early factors seem to be linked to a better establishment of these beneficial bacteria and therefore to higher levels of 4-OH-PLA: 

  • vaginal delivery, which allows the child to acquire part of the mother’s microbiota, including bifidobacteria;
  • the presence of older siblings, also sources of joyful (and beneficial!) bacterial exchange;
  • and, above all, exclusive breastfeeding during the first two months, which supports the development of natural protection mechanisms against allergies.

These findings show how much the early months matter in shaping the microbiota–immunity pathway, crucial in the first 1,000 days of life.

Source

1. Myers PN, Dehli RK, Mie A et al. Early-life colonization by aromatic-lactate-producing bifidobacteria lowers the risk of allergic sensitization. Nat Microbiol. 2026 Feb;11(2):429-441. 

Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Xpeer course: The Gut Microbiome in Immuno-Oncology

Join Dr. Arielle Elkrief in this free CME-accredited course as she explores the role of the gut microbiome in shaping response and resistance to immune checkpoint inhibitors in patients with solid tumors.

Image

Synopsis of the course

This CME-accredited session explores the critical role of the gut microbiome in shaping response and resistance to immune checkpoint inhibitors in patients with solid tumors. It examines the impact of antibiotic use on treatment outcomes, highlighting the mechanisms underlying antibiotic-mediated resistance and the importance of antimicrobial stewardship in oncology care. The session also reviews emerging strategies to modulate the gut microbiome, including experimental approaches under investigation in clinical trials. Participants will gain insight into how microbiome-targeted interventions may enhance immunotherapy effectiveness and inform future clinical practice.

Who is Arielle Elkrief?

Dr. Arielle Elkrief is a medical oncologist and clinician-scientist at the Centre hospitalier de l’Université de Montréal and Assistant Professor at the Université de Montréal. She co-directs the CHUM Microbiome Centre, where her research focuses on the role of the gut and tumor microbiome in cancer immunotherapy and the development of microbiome-based therapeutic strategies.

What is Xpeer?

  • Xpeer Medical Education is the first accredited medical education app in the market, with video microlearning engaging videos of just 5 minutes.
  • With a powerful algorithm to personalize the user experience and the contents as the most popular entertaining streaming platforms, it offers a brand new experience for the continuing education and professional development of the healthcare professionals.
  • Accredited by the European Union of Medical Specialists, it delivers high quality scientific medical education pieces. On Xpeer, you will find this curriculum on Microbiota and 500 hours of medical education in 2021 in your specialty, technologies and professional and personal skills.

Information on accreditation

The app Xpeer is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide official ECMEC credits recognized officially in 26 countries.

The credits for the users of the module will be 1 European CME credit (ECMEC®) for every hour (60 minutes of actual e-learning excluding introductions etc.) of use, provided that the users have completed a module and have passed the relevant assessment.

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Article Off

Bifidobacteria: early allies against allergic risk?

Certain intestinal bifidobacteria, supported in particular by breastfeeding, seem to reduce an infant’s future allergic risk by modulating IgE production.

Vaginal birth, presence of siblings, pets, living in rural settings : all early exposures that shape immune system development. Everything appears to be decided very early: the presence in infants’ blood of IgE specific to food sensitivity is an early indicator of impaired immune tolerance and future development of allergic diseases. Could gut microbiota play a key role?

16% Food allergen sensitization affects up to 16% of all infants in low- and high-income countries. ¹

Infant-type ALDH+ Bifidobacterium strains

Researchers examined changes in the gut flora of 56 full-term Swedish infants from the ALADDIN cohort 1 followed until age 5. While they were breastfed, their microbiota were dominated largely by Bifidobacterium species carrying the aromatic lactate dehydrogenase (ALDH) gene, including B. bifidum and B. longum, as well as B. infantis and B. breve. The ALDH enzyme catalyzes the final step in converting aromatic amino acids into aromatic lactates (including 4-hydroxyphenyl lactate, or 4-OH-PLA). These aromatic lactates modulate host immunity, although it remains unknown whether they regulate IgE.

x14 Vaginal delivery was associated with a 14-fold higher odds of maternal strain colonization than caesarean section. ¹

A link between bifidobacteria and IgE

This leads to a question from the team: is this early abundance of ALDH+ bifidobacteria associated with allergic sensitization and circulating IgE? Data from 146 children in the same cohort show that ALDH+ bifidobacteria are more abundant in children without food allergen-specific IgE. Conversely, ALDH- bifidobacteria are more abundant in children with such IgE. This association is confirmed in the German PAPS cohort 2.
The levels of aromatic lactates produced by intestinal ALDH+ bifidobacteria during the breastfeeding phase are therefore associated inversely with circulating allergen-specific IgE levels in early childhood.And also with atopic dermatitis at age 2.

½ At preschool age, up to half of the children with circulating IgE against common food allergens in infancy are reported to develop food allergy. ¹

Protective effect of a bifidobacterial metabolite

The microbial metabolite 4-OH-PLA, which specifically inhibits IgE production (without affecting IgG), could explain 40% of the inverse association between the presence of ALDH+ bifidobacteria and circulating IgE levels.
This protective association seems limited to an early immune window (before 5 months of age), when 4-OH-PLA is most abundant in the infant intestine. As solid foods are introduced, its levels drop sharply.

Therefore, an early interaction among gut microbiota, bacterial metabolites and immunity seems to influence allergic sensitivity, reinforcing the importance of the first 1,000 days. In this regard, vaginal delivery, the presence of siblings, and exclusive breastfeeding were each associated with higher 4-OH-PLA levels in stools at 2 months of age, while early introduction of infant formula reduced them. This is yet another reason to support breastfeeding when possible.

Does breast milk wire the infant resistome?

Learn more
Summary
Off
Sidebar
On
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
News Off

Vaginal microbiota #24

By Prof. Satu Pekkala
Academy of Finland Research Fellow, Faculty of Sport
and Health Sciences, University of Jyväskylä, Finland

Actu PRO : Un catalogue des gènes du microbiote vaginal

Gut–mind–pelvic axis: New insights from microbiome science

Beyond surgery, hormones and tumor staging, women with endometrial cancer often experience persistent symptoms affecting mental Beyond surgery, hormones and tumor staging, women with endometrial cancer often experience persistent symptoms
affecting mental health, gastrointestinal comfort and sexual well-being. A recent study from the University of Oklahoma suggests that the gut and vaginal microbiota may contribute to these quality-oflife outcomes.

Researchers followed 140 women scheduled for hysterectomy, including patients with endometrial cancer and women with benign gynecological conditions. Before surgery, participants completed validated questionnaires assessing physical and mental health, stress, gastrointestinal symptoms and sexual function. Vaginal and rectal samples were collected for microbiome analysis, enabling correlations between microbial profiles and patient-reported outcomes.

Women with endometrial cancer showed higher vaginal microbial diversity, a pattern usually considered unfavorable in other clinical contexts. Greater diversity was associated with increased vaginal dryness and irritation. Several bacterial species, including Lactobacillus iners, Lactobacillus gasseri and Streptococcus agalactiae, were more frequent in women reporting worse vaginal symptoms, suggesting that oncological conditions may alter vaginal ecosystem dynamics.

The gut microbiota also displayed meaningful associations. In endometrial cancer patients, certain bacterial taxa correlated with better mental well-being, lower stress levels and fewer gastrointestinal complaints, while others were linked to bloating, discomfort or reduced
sexual interest.

These findings reinforce the concept of a gut–mind–pelvic axis connecting microbial ecosystems with psychological and pelvic health.
From a clinical perspective, this work opens new opportunities for precision microbiome interventions, from targeted probiotics to dietary strategies in supportive cancer care. Microbiome profiling could help identify patients at risk of persistent symptoms and guide personalized interventions, including dietary strategies, lifestyle interventions or targeted microbiota modulation, with the aim of improving quality of life alongside standard oncological treatments.

Gautam NJ, Jimenez NR, Łaniewski P, et al. Microbiome impacts quality of life in patients with endometrial cancer and benign gynecological conditions. Qual Life Res 2025 ; 34: 2935-48.

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Congress review Off

Gut microbiota #24

By Prof. Satu Pekkala
Academy of Finland Research Fellow, Faculty of Sport
and Health Sciences, University of Jyväskylä, Finland

Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy

Sedentary lifestyle increases cancer risk, and exercise is known to enhance immune checkpoint inhibitor (ICI) efficacy. However, the mechanisms have remained largely unknown. Gut microbiota promotes antitumor immunity and exercise modulates gut microbiota, but
whether these factors are linked has not been studied. Phelps et al. used preclinical cancer models to explore possible connections.

They found that prolonged exercise limited melanoma tumor growth without affecting body weight. Exercise also boosted CD4 and CD8 T cells in tumor-draining lymph nodes. Importantly, this effect required gut microbiota, which was involved in exercise-induced antitumor activity. To establish causality, the authors performed fecal microbial transplantations (FMTs) into antibiotic-treated mice using feces from exercised and sedentary donors. FMT from exercised mice suppressed tumor growth, prolonged survival, and enhanced tumor immunity. While bacterial cell wall components are known to increase immune responses, the exercise- FMT effect appeared dependent on microbiota-derived metabolites.

Indeed, oral administration of microbial metabolites from exercised mice’s feces restrained melanoma tumor growth. To understand the role of metabolites, the authors used targeted metabolomics of 1-carbon (1C) metabolites and found that mainly precursors of the folate-dependent 1C pathway were diminished in exercised mice. Further experiments revealed that elevated formate levels promoted
antitumor immunity and restrained tumor growth, and that exercise specifically increased formate. In addition to melanoma, these effects were observed in adenocarcinoma and lymphoma models. Formate also dramatically reduced lung metastases. Formate’s effect on antitumor immunity was mediated via nuclear factor erythroid 2-related factor-2. Ultimately, they provide some translational evidence
that high-formate-producing human microbiota is associated with enhanced tumor suppression and immunity.

Phelps CM, Willis NB, Duan T, et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell 2025; 188: 5680-700.

Temporal dynamics and microbial interactions shaping the gut resistome in early infancy

Antibiotic resistance stems from antibiotic resistance genes (ARGs), which enable bacteria to withstand antibiotics. ARGs existed before human antibiotic use, but modern overuse has amplified their prevalence globally. When resistance reaches pathogenic microbes, it threatens public health by undermining antibiotics. However, more studies, especially in infancy are needed to understand gut resistome’s role in spreading antimicrobial resistance (AMR).

This study investigated infant gut resistome dynamics in a birth cohort with longitudinally collected fecal samples 8 times from birth up to five years of age. Early in infancy (3–6 days to 2 months), ARG richness showed a bimodal pattern, which disappeared by 6 months as most infants exhibited high ARG counts. At 12 months, bimodality reappeared, followed by a decline of ARGs at 60 months. ARG abundance relative to total genes was highest in the first 6 months and dropped after 12 months. Absolute ARG abundance varied largely between infants during the first 2 months of life, peaked at 6 months, and then dropped at 12 months.

It was further found that ARGs conferring resistance against tetracyclines, fluoroquinolones, penams, and cephalosporins were the most common and the most abundant until 6 months of age. ARGs against tetracyclines and fluoroquinolones remained the most common across all ages. ARG relative and absolute abundance did not differ between antibiotic-naïve infants and those exposed to antibiotics before the 1st sample at 3–6 days of life. Interestingly, microbial composition and birth mode seem to influence ARG diversity, while only few bacterial taxa have high number of ARGs. To conclude, this study revealed key temporal patterns and microbial interactions that shape the early-infant gut resistome, suggesting opportunities for targeted strategies to limit AMR during this critical developmental stage.

Chatzigiannidou I, Johansen PL, Dehli RK, et al. Temporal dynamics and microbial interactions shaping the gut resistome in early infancy. Nat Commun 2025; 16: 8139

Quantifying the varying harvest of fermentation products from the human gut microbiota

The gut microbiota influences the host largely through the exchange of fermentation products, mainly short-chain fatty acids produced by microbes in the large intestine. The microbes metabolize complex carbohydrates from plant-based foods, as well as dietary proteins that escape digestion in the small intestine. While metabolomics can identify a wide variety of compounds, it gives only snapshots and provides little insight into the overall flux of fermentation products that microbes produce and that host’s body takes up. To overcome this limit, this study established orthogonal approaches to quantify this flux, integrating data on bacterial metabolism, digestive physiology, and metagenomics.

This framework allowed creating many important findings. For instance, the bulk of carbon in microbiota-available carbohydrates, 90%, ended up in fermentation products, which were mostly taken up by the host. Variation in diet largely determined the total yield of fermentation products. Low yields may occur when diets are rich in highly processed foods lacking complex carbohydrates or when they include carbohydrates that resist digestion and pass through the gut unchanged. Somewhat surprisingly, the microbes themselves had less impact on the total daily fermentation product harvest, excluding some specific fermentation products, such as butyrate and lactate.


While not being the main aim of the study, it was found that mice harvest far more fermentation products per body weight than humans (≈400 mmol/kg/day vs. 7 mmol/kg/day), contributing over 21% of their daily energy needs compared to 1.7–12.1% in humans. Combined with differences in microbiome composition and gut anatomy, this disparity must be considered when extrapolating mouse data to human systemic effects. The authors conclude that due to dynamic, flowing environment of the intestine, developing this type of framework is critical to move away from assumptions based on point measurements of metabolites toward an integrated model of host-microbiome functions in health and disease.

 

Arnoldini M, Sharma R, Moresi C, et al. Quantifying the varying harvest of fermentation products from the human gut microbiota. Cell 2025 ; 188 : 5332-42.

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Press review Off

PFAS and microbiota

By Anaïs Bodon, Muriel Mercier-Bonin, Bruno Sovran
Neuro-Gastroenterology and Nutrition Team at INRAE (National Research Institute for Agriculture, Food and Environment), Toxalim, Toulouse, France

Per- and polyfluoroalkyl substances (PFAS) are a large family of chemical compounds commonly referred to as “forever chemicals” due to their extreme persistence in the environment and ecosystems. Their fire-retardant, water-repellent, and heat-resistant properties have led
to their widespread use in many everyday products (nonstick cookware, waterproof textiles, etc.). PFAS are highly resistant to degradation, accumulate in the environment, contaminate the food chain, and lead to widespread human exposure. PFAS thus accumulate in the body with documented health effects, albeit for a limited number of compounds.

Are the claims made on social media justified?

In the laboratory, under very specific experimental conditions, certain bacteria in the gut microbiota 1 or lactic acid bacteria 2 (often used as probiotics) can bioaccumulate PFAS or “sequester” them on their surface, suggesting a possible “detoxification effect.” In practice, however, ingested PFAS are almost entirely absorbed in the small intestine and rapidly enter the bloodstream. The gut microbiota is mainly
located in the colon, a compartment that is only minimally exposed to PFAS, although a small fraction of the microbiota, located in the small intestine, is directly exposed. As a result, direct contact between PFAS and intestinal bacteria remains marginal compared with the total amount of PFAS already accumulated in the body. Based on current knowledge, it is therefore difficult to conclude that the microbiota and/or probiotic intake play a major role, contrary to what is suggested in the media, in the microbial detoxification of total PFAS from the body.

What are the impacts on the microbiota?

Furthermore, this limited contact may nevertheless contribute to the increasingly documented effects of PFAS on the gut microbiota. Studies in rodents show that PFAS exposure can alter the composition of the microbiota and disrupt some of its functions, including metabolites production and interactions with the immune system 3,4. These alterations have been shown to disrupt the balance of the digestive ecosystem and impair intestinal health.

Are there any important limitations to keep in mind?

Most of the available scientific data comes from animal models exposed to doses generally higher than those representative of human exposure, and concerns a very limited number of PFAS, often studied individually. In humans, studies remain rare, mainly observational, and influenced by many confounding factors (e.g. diet, age, sex). Research on PFAS-microbiota interactions is therefore still emerging.

What are the implications for healthcare professionals and how should they respond to patients?

Given the media coverage of the topic and patients’ concerns, it is essential to communicate on the basis of scientific evidence, without excessive extrapolation. It should be explained that there is no “miracle” solution for PFAS detoxification, particularly through probiotics.

In practice, healthcare professionals can advise limiting known sources of PFAS exposure (e.g. food packaging, non-stick cookware) and encouraging a varied, minimally processed diet rich in fruits, vegetables, and whole grains to support the protective function of the microbiota.

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Expert opinion Off

Microbiota and Pediatric Health: Highlights from LASPGHAN 2025

By Prof. Natascha Sandy
Clínica Levy, Condomínio Atlantis, Sao Paulo, Brazil

The 25th Congress of the Latin American Society for Pediatric Gastroenterology, Hepatology and Nutrition (LASPGHAN), held in Mérida, reinforced the central role of the microbiota in pediatric health and disease. The discussions emphasized a rigorous, evidence-based and strain-specific approach to probiotic use, aligned with the most recent ESPGHAN position paper and the forthcoming LASPGHAN consensus. The focus has shifted from empirical supplementation to indications supported by randomized clinical trials and meta-analyses, highlighting how microbial modulation can influence gastrointestinal, immune and metabolic outcomes across different stages of childhood. There is increasing recognition that early-life microbiota imprinting may have lifelong consequences for metabolic programming and immune tolerance, emphasizing the importance of perinatal nutrition,
breastfeeding, and the avoidance of unnecessary antibiotics as key determinants of microbial resilience.

Acute infectious diarrhea

Current guidelines recommend certain strains of Saccharomyces and Lacticaseibacillus as the best-documented strains for acute gastroenteritis and prevention of antibiotic-associated diarrhea in children 1-4. Randomized controlled trials and meta-analyses consistently demonstrate a clinically relevant reduction in illness duration and stool frequency when these probiotics are used together with oral
rehydration therapy. For antibiotic-associated diarrhea, both strains maintain moderate-quality evidence and favorable safety profiles, making them the most reliable options in routine pediatric care. Some Limosilactobacillus may also be considered in acute diarrhea and infantile colic, reflecting the increasing understanding that early-life microbial modulation supports immune tolerance and intestinal barrier maturation 5. Beyond probiotics alone, emerging studies presented at LASPGHAN explored how combinations with prebiotic substrates can accelerate the restoration of microbiota diversity after infection or antibiotic exposure. This synergistic “biotic” approach may represent a new frontier for preventing recurrence and enhancing gut recovery in children.

Functional gastrointestinal disorders and colic

Beyond acute settings, the role of probiotics in functional gastrointestinal disorders is being more cautiously defined. Some strains of Lacticaseibacillus have shown potential to reduce the frequency of abdominal pain and improve quality of life in functional abdominal pain and irritable bowel syndrome when combined with dietary and behavioral measures 1, 3. The overall strength of evidence remains
modest, but emerging data suggest a role for specific strains as adjuvants within a multimodal management approach. In functional constipation, Lacticaseibacillus may also be used as an adjunct to standard therapy, while in infantile colic it remains the most consistently recommended strain. Preventive use of Lacticaseibacillus from birth to four months has been associated with lower incidence of colic in high-risk infants 2. Strain selection should always consider patient phenotype, symptom pattern, and concomitant interventions such as fiber intake or behavioral therapy. Integrating probiotics or synbiotics into a holistic management strategy—rather than using them as isolated supplements—emerges as a key principle for optimizing outcomes in functional gastrointestinal disorders.

Food allergy and mucosal immunity

Increasing attention has been directed to the interaction between microbiota and immune development. Lacticaseibacillus administered for at least three months may help promote tolerance and clinical improvement in cow’s-milk protein allergy 1 ,2. These findings are biologically plausible given the immunomodulatory properties of the strain and its capacity to influence epithelial and cytokine responses. Nevertheless,
further studies are needed to validate the magnitude and durability of these effects in long-term allergic outcomes.

Necrotizing enterocolitis prevention

Prophylactic use of certain strains of Lacticaseibacillus greater than or equal to 30 days remains supported for reducing necrotizing enterocolitis and mortality, provided that product quality, strain identity and clinical surveillance are ensured in preterm infants 1. The benefit appears to be strain-dependent, underlining the need for standardized formulations and microbiological traceability in neonatal care. Recent evidence highlights how early microbial exposure—through vaginal delivery, breastfeeding, and dietary diversification— modulates mucosal immunity and oral tolerance. The concept of the “first 1,000 days” remains a crucial window for interventions aiming to prevent allergic and inflammatory diseases. Growing data on postbiotics, non-viable microbial products with signaling and anti-inflammatory potential, are opening new therapeutic perspectives in allergy prevention and immune education.

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Congress review Off

Symptom-specific gut microbial and metabolic profiles in ADHD reveal SCFA deficiency as a key pathogenic mechanism

By Prof. Emmanuel Mas
Gastroenterology and Nutrition Department,
Children’s Hospital, Toulouse, France

Comments on the original article by Wang et al. (Gut Microbes 2025) 1

Previous evidence links gut microbiota to attention-deficit/ hyperactivity disorder (ADHD) through the gut-brain axis. However, the specific microbiota contributing to symptoms remain unclear. To characterise the gut microbial profile linked to different symptoms and explore the mediation mechanism between microbiota alterations and the main ADHD symptoms, the authors of the article conducted shotgun metagenomic sequencing and faecal metabolomics analysis on 94 ADHD patients and 94 age- and gender-matched controls. They analysed the microbial characteristics of three subgroups presenting with different main
symptoms of ADHD. Faecal microbiota transplantation in mice validated the hypothesis that gut microbial composition affects ADHD symptoms through metabolic alterations. This study provided further insight into the mechanisms underlying metabolic disturbances in ADHD and shed light on the role of gut microbiota in these processes.

What do we already know about this subject?

Attention deficit hyperactivity disorder (ADHD) is common in paediatrics, with a 3-5% prevalence. Various environmental factors play a role in the development of ADHD, including perinatal, social-emotional and nutritional factors. These risk factors also influence the gut microbiota (GM). Early alterations can disrupt neurological development. These effects could be mediated by the microbiota-gut-brain axis through three pathways (immune, neuronal and endocrine/systemic).

Figure 1 - Specific differences in bacterial taxa between each of the ADHD groups.

Image

What are the main insights from this study?

One hundred and eighty-eight (188) children were included in a single-centre Chinese study, including 94 children with ADHD who were divided into three subgroups, 56 with predominant inattention symptoms (group IA), 9 with predominant hyperactivity-impulsivity symptoms (group HA) and 29 with combined symptoms (group C), and 94 controls (group TD).

The GM analysis found no difference between these three groups in terms of bacterial richness and diversity, the relative abundance of the 10 main genera and the Firmicutes/Bacteroidetes ratio. However, specific taxa were associated with ADHD subtypes (figure 1).

The GM analysis found no difference between these three groups in terms of bacterial richness and diversity, the relative abundance of the 10 main genera and the Firmicutes/Bacteroidetes ratio. However, specific taxa were associated with ADHD subtypes (figure 1).
The family Lactobacillaceae and species Lactobacillus sanfranciscencis were enriched in the TD group. The TD group had more Bifidobacteriales than group C. In groups IA and C (inattention symptoms), the genus Streptococcus and species Streptococcus salivarius were identified as harmful bacteria, while family Flavobacteriaceae, genus Paraprevotella, genus Fructilactobacillus, species Paraprevotella xylaniphila, and species Phocaeicola salanitronis were beneficial. In groups HA and C (hyperactivity-impulsivity symptoms), the family Lactobacillaceae and species Lactobacillus sanfranciscencis were beneficial (figure 1).


The metabolomic profiles of ADHD children revealed disturbances in fatty-acid synthesis, with a significant reduction in the synthesis of unsaturated fatty acids and linoleic acid, as well as amino-acid metabolism (figure 2). The various symptoms, inattention, hyperactivity and impulsivity, were negatively correlated with different metabolites, imidazoleacetic acid and inattention (p<0.001). Thus, Lactobacillus
sanfranciscencis
had a direct effect and an effect mediated by imidazoleacetic acid on inattention.

An experiment with three cycles of faecal microbiota transfer (FMT) from children with ADHD and a low abundance of beneficial Lactobacillus sanfranciscencis bacteria (FMT-A group) and controls (FMT-H group) was conducted in four-week-old male C57BL/6J mice. The mice then received either Lactobacillus sanfranciscencis (1 x108 organisms/mouse/day, group FMT-A-R1), or 150 mmol/L sodium acetate (group FMT-A-R2) or PBS for the controls (group FMT-A-C). Hyperactivity symptoms improved significantly in the FMT-A-R1 group but not in the FMT-A-R2 group, while inattention symptoms improved in both groups. Finally, fatty-acid and unsaturated
fatty-acid synthesis was improved in the FMT-A-R1 and FMT-A-R2 groups versus FMT-A-C (figure 3).

Figure 2 - Alteration of the different metabolic pathways, size of the circles corresponding to the number of genes involved.

Image

Figure 3 - Faecal transplantation with stools from ADHD children reduces fatty-acid synthesis, which is corrected by treatment with Lactobacillus sanfranciscencis or sodium acetate.

Image

What are the consequences in practice?

This study showed that GM alterations in ADHD children were symptom-dependent. The sub-group analysis showed that family Lactobacillaceae and species Lactobacillus sanfranciscencis were enriched in the TD group. In addition, after faecal transplantation with ADHD stools, treatment with Lactobacillus sanfranciscencis improved symptoms.

Fatty-acid and unsaturated fatty-acid synthesis was reduced in ADHD children. Similarly, after faecal transplantation with ADHD stools, treatment with short-chain fatty acids (imidazoleacetic acid) led to an improvement in symptoms.

Point clé
  • Gut microbiota alterations are specifically associated with the different symptoms of ADHD children. This effect is mediated by disturbances in fatty-acid metabolism

CONCLUSION

The findings of this study add to our understanding of the role the gut microbiota plays in children with ADHD, with metabolic
alterations involved in the disturbance of the microbiota-gutbrain axis in this context.

Summary
Off
Sidebar
Off
Migrated content
Désactivé
Updated content
Désactivé
Hide image
Off
Commented article Off